Kinetic analysis of drug-induced G2 block in vitro.
The data on cell-cycle effects of two prospective antitumour agents, (+)-1,2,-bis(3,5-dioxopiperazine-1-yl)propane (soluble ICRF; NSC 169780) and 1,4-bis(2'chloroethyl)-1,4-diazabicyclo [2.2.1] heptane diperchlorate (CBH; NSC 57198) were used to determine whether a modified stathmokinetic experiment could predict the effects of continuous, long-term (0-48 hr) drug exposure in an in vitro L1210 murine leukaemia cell system. Generally, continuous drug exposure of exponentially growing cells does not provide sufficient quantitative information concerning cell-cycle-phase-specific mechanisms of drug action. Alternatively, stathmokinetic experiments, which are usually limited to some fraction of one cell doubling time, provide little information about long-term drug effects. By using mathematical models constructed for this purpose, however, stathmokinetic data can predict the overall proportion of cells affected by a drug though failing to discern between various kinds of drug action (e.g. reversible v. irreversible block, blocking v. killing action, etc.), especially when it occurs in G2 phase. In addition, it can be shown that for at least one of the drugs (soluble ICRF) the stathmokinetic experiment fails to predict 'after-effects' of drug treatment which extend into the following cell cycle(s). It also becomes clear that the degradation of exponential growth characteristics of quickly dividing cells during long-term, continuous drug exposure makes prediction of cell-cycle kinetic perturbations uncertain when derived from short-duration stathmokinetic experiments. However, with care, the joint application of 'short term' (e.g. stathmokinesis) and 'long term' (e.g. continuous exposure) techniques allow adequate quantitative insight into drug-perturbed cell-cycle kinetics. The applicability of modelling techniques is discussed: in the present instance it is limited to lower drug concentrations. For higher drug concentrations, effects like increased ploidy, ineffective division, etc., make it impossible in the present study to obtain a clear picture of the kinetics.
D000818:Animals; D000970:Antineoplastic Agents; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic; D001952:Bridged-Ring Compounds / Q000494:pharmacology*; D007399:Interphase / Q000187:drug effects*; D007700:Kinetics; D007939:Leukemia L1210 / Q000188:drug therapy; D008433:Mathematics; D051379:Mice; D008954:Models, Biological; D010879:Piperazines / Q000494:pharmacology*; D011929:Razoxane / Q000494:pharmacology*
D000970:Antineoplastic Agents; D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D001952:Bridged-Ring Compounds; D010879:Piperazines; C024006:1,4-bis(2'-chloroethyl)-1,4-diazabicyclo(2.2.1)heptane; D011929:Razoxane